BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9643566)

  • 1. Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance.
    Meckenstock G; Aul C; Hildebrandt B; Heyll A; Germing U; Wehmeier A; Giagounidis A; Suedhoff T; Burk M; Soehngen D; Schneider W
    Leuk Lymphoma; 1998 May; 29(5-6):523-31. PubMed ID: 9643566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.
    Gahn B; Haase D; Unterhalt M; Drescher M; Schoch C; Fonatsch C; Terstappen LW; Hiddemann W; Büchner T; Bennett JM; Wörmann B
    Leukemia; 1996 Jun; 10(6):946-51. PubMed ID: 8667650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
    Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
    J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.
    Schmetzer HM; Braun S; Wiesner D; Duell T; Gerhartz HH; Mittermueller J
    Acta Haematol; 2000; 103(3):125-34. PubMed ID: 10940650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
    Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
    Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R; Venditti A; Del Poeta G; Aronica G; Dentamaro T; Cecconi M; Stipa E; Scimò MT; Masi M; Amadori S
    Cancer; 1996 Jun; 77(12):2476-88. PubMed ID: 8640696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients.
    Perea G; Domingo A; Villamor N; Palacios C; Juncà J; Torres P; Llorente A; Fernández C; Tormo M; Queipo de Llano MP; Bargay J; Gallart M; Florensa L; Vivancos P; Martí JM; Font L; Berlanga J; Esteve J; Bueno J; Ribera JM; Brunet S; Sierra J; Nomdedéu JF;
    Leuk Res; 2005 Oct; 29(10):1109-16. PubMed ID: 16095690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings.
    Cuneo A; Ferrant A; Michaux JL; Boogaerts M; Demuynck H; Van Orshoven A; Criel A; Stul M; Dal Cin P; Hernandez J
    Blood; 1995 Jun; 85(12):3688-94. PubMed ID: 7780152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
    Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
    de Nully Brown P; Jurlander J; Pedersen-Bjergaard J; Victor MA; Geisler CH
    Leuk Res; 1997 Oct; 21(10):985-95. PubMed ID: 9403009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
    Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
    Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML).
    Lamy T; Goasguen JE; Mordelet E; Grulois I; Dauriac C; Drenou B; Chaperon J; Fauchet R; le Prise PY
    Leukemia; 1994 Nov; 8(11):1879-83. PubMed ID: 7526090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
    Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
    Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
    Iwakiri R; Ohta M; Mikoshiba M; Tsutsumi H; Kumakawa T; Mori M
    Int J Hematol; 2002 Jan; 75(1):45-50. PubMed ID: 11843290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype.
    Cuneo A; Bigoni R; Cavazzini F; Bardi A; Roberti MG; Agostini P; Tammiso E; Ciccone N; Mancini M; Nanni M; De Cuia R; Divona M; La Starza R; Crescenzi B; Testoni N; Rege Cambrin G; Mecucci C; Lo Coco F; Saglio G; Castoldi G
    Leukemia; 2002 Sep; 16(9):1745-51. PubMed ID: 12200689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.